The adjacent immunosuppressant, mycophenolate–mofetil or mTOR inhibitor, was either halved in 18 (19.1%), minimized in 28 (29.8%), withheld in 20 (21.3%) or left unchanged in 27 (28.7%) participants depending on the COVID-19 severity. This evidence concerns the gene MTOR and COVID-19.